Format

Send to

Choose Destination
Indian J Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):628-31.

Topical immunotherapy with diphenylcyclopropenone in vitiligo: a preliminary experience.

Author information

1
Department of Dermatology, Jahrom University of Medical Sciences, Jahrom, Iran. shahinaghaei@yahoo.com

Abstract

BACKGROUND:

Despite recent significant therapeutic advances, vitiligo remains a clinical conundrum. Topical immunotherapy has been extensively tested in the treatment of various dermatologic disorders, especially those believed to have an immunologic basis.

AIM:

To evaluate the role of topical diphenylcyclopropenone (DPCP) in the treatment of vitiligo.

METHODS:

Nineteen patients with limited vitiligo lesions were enrolled in this study. After sensitization with 2% lotion of DPCP in acetone, progressively higher concentrations beginning at 0.001% up to 2% were applied weekly for 6 months to the depigmented skin lesions.

RESULTS:

Thirteen of the 19 patients were evaluated at the end of 6 months. Four patients with focal vitiligo, one patient with vitiligo vulgaris, and three patients with segmental vitiligo showed marked (grade 3) repigmentation.

CONCLUSION:

Marginal and central repigmentation with hyperpigmented borders was seen in the majority of lesions. Further controlled trials should be undertaken to evaluate the use of topical DPCP in vitiligo.

PMID:
19171989
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center